Your browser doesn't support javascript.
loading
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)
Pérez-Valderrama, Begoña; González-del-Alba, Aránzazu; Morales-Barrera, Rafael; Peláez Fernández, Ignacio; Vázquez, Sergio; Caballero Díaz, Cristina; Domènech, Montserrat; Fernández Calvo, Ovidio; Gómez de Liaño Lista, Alfonso; Arranz Arija, José Ángel.
Affiliation
  • Pérez-Valderrama, Begoña; Hospital Universitario Virgen del Rocío. Sevilla. Spain
  • González-del-Alba, Aránzazu; Hospital Universitario Puerta de Hierro Majadahonda. Madrid. Spain
  • Morales-Barrera, Rafael; Vall d’Hebron Institute of Oncology. Barcelona. Spain
  • Peláez Fernández, Ignacio; Hospital Universitario de Cabueñes. Gijón. Spain
  • Vázquez, Sergio; Hospital Universitario Lucus Augusti. Lugo. Spain
  • Caballero Díaz, Cristina; Hospital General Universitario de Valencia. Valencia. Spain
  • Domènech, Montserrat; Hospital Fundació Althaia. Manresa. Spain
  • Fernández Calvo, Ovidio; Complejo Hospitalario Universitario. Ourense. Spain
  • Gómez de Liaño Lista, Alfonso; Complejo Hospitalario Universitario Insular-Materno Infantil. Las Palmas. Spain
  • Arranz Arija, José Ángel; Hospital General Universitario Gregorio Marañón. Madrid. Spain
Clin. transl. oncol. (Print) ; 24(4): 613-624, abril 2022.
Article in English | IBECS | ID: ibc-203765
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Most muscle-invasive bladder cancer (BC) are urothelial carcinomas (UC) of transitional origin, although histological variants of UC have been recognized. Smoking is the most important risk factor in developed countries, and the basis for prevention. UC harbors high number of genomic aberrations that make possible targeted therapies. Based on molecular features, a consensus classification identified six different MIBC subtypes. Hematuria and irritative bladder symptoms, CT scan, cystoscopy and transurethral resection are the basis for diagnosis. Radical cystectomy with pelvic lymphadenectomy is the standard approach for muscle-invasive BC, although bladder preservation is an option for selected patients who wish to avoid or cannot tolerate surgery. Perioperative cisplatin-based neoadjuvant chemotherapy is recommended for cT2-4aN0M0 tumors, or as adjuvant in patients with pT3/4 and or pN + after radical cystectomy. Follow-up is particularly important after the availability of new salvage therapies. It should be individualized and adapted to the risk of recurrence. Cisplatin–gemcitabine is considered the standard first line for metastatic tumors. Carboplatin should replace cisplatin in cisplatin-ineligible patients. According to the EMA label, pembrolizumab or atezolizumab could be an option in cisplatin-ineligible patients with high PD-L1 expression. For patients whose disease respond or did not progress after first-line platinum chemotherapy, maintenance with avelumab prolongs survival with respect to the best supportive care. Pembrolizumab also increases survival versus vinflunine or taxanes in patients with progression after chemotherapy who have not received avelumab, as well as enfortumab vedotin in those progressing to first-line chemotherapy followed by an antiPDL1/PD1. Erdafitinib may be considered in this setting in patients with FGFR alterations. An early onset of supportive and palliative care is always strongly recommended.
Subject(s)


Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Antineoplastic Combined Chemotherapy Protocols / Cisplatin Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2022 Document type: Article Institution/Affiliation country: Complejo Hospitalario Universitario Insular-Materno Infantil/Spain / Complejo Hospitalario Universitario/Spain / Hospital Fundació Althaia/Spain / Hospital General Universitario Gregorio Marañón/Spain / Hospital General Universitario de Valencia/Spain / Hospital Universitario Lucus Augusti/Spain / Hospital Universitario Puerta de Hierro Majadahonda/Spain / Hospital Universitario Virgen del Rocío/Spain / Hospital Universitario de Cabueñes/Spain / Vall d’Hebron Institute of Oncology/Spain

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Antineoplastic Combined Chemotherapy Protocols / Cisplatin Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2022 Document type: Article Institution/Affiliation country: Complejo Hospitalario Universitario Insular-Materno Infantil/Spain / Complejo Hospitalario Universitario/Spain / Hospital Fundació Althaia/Spain / Hospital General Universitario Gregorio Marañón/Spain / Hospital General Universitario de Valencia/Spain / Hospital Universitario Lucus Augusti/Spain / Hospital Universitario Puerta de Hierro Majadahonda/Spain / Hospital Universitario Virgen del Rocío/Spain / Hospital Universitario de Cabueñes/Spain / Vall d’Hebron Institute of Oncology/Spain
...